Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.573
-0.017 (-2.95%)
Apr 29, 2026, 12:31 PM EDT - Market open
Kairos Pharma Employees
As of December 31, 2025, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,361,750
Market Cap
12.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - |
| Dec 31, 2024 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| BioCardia | 21 |
| Moleculin Biotech | 17 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
| Intensity Therapeutics | 7 |
| Traws Pharma | 7 |
| Phio Pharmaceuticals | 6 |
KAPA News
- 13 hours ago - KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 14 days ago - Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation - Business Wire
- 2 months ago - Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics - Business Wire
- 2 months ago - Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics - Business Wire
- 3 months ago - Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference - Business Wire
- 4 months ago - Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer - Business Wire
- 6 months ago - Kairos Pharma Provides Shareholder Update - Business Wire
- 6 months ago - Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting - Business Wire